Journal of Glycobiology
Open Access

Impartial Glycomics: A Great Tool for Identifying and Investigating Atypical Disorders

Stern Moss^{* *}Correspondence: Stern Moss, Department of Experimental Biochemistry, Institute for Medical Biology, University of Tromso, Tromso, Norway, Email:

Author info »

Description

Glycomics is a subset of glycobiology that tries to determine the structure and function of the entire set of glycans (the glycome) produced in a cell or organism, as well as all the genes that code for glycoproteins. However, several disorders have been identified and investigated in this system. The Program for Undiagnosed Diseases (PUD) investigates unusual genetic illnesses in order to better understand human biology as well as to find diagnosis. The PUD employed mass spectrometry to agnostically identify anomalies of N-linked and O-linked glycans in plasma and free oligosaccharides in the urine of 207 patients to determine the role of protein glycosylation in uncommon disorders. In at least one fluid, 60% of PUD patients exhibited a glycome profile that differed from control values. In 66 patients with anomalies in plasma and/or urine, further analysis of the fibroblast glycome revealed a consistent glycome pattern in 83 percent of cases. Since it's doubtful that all of these people have Congenital Disorders of Glycosylation (CDGs), many of them may have secondary glycosylation problems (CDGs). In fact, full exome sequencing identified just a few patients who had CDGs, as well as a few others who had diseases that affected glycosylation indirectly. In summary, provide a biochemical phenotyping screen for identifying protein glycosylation abnormalities in PUD patients, which might help unravel illness causes. Rare disorders are characterized by primary adaption problems caused by genetic mutations, and common disorders are characterized by conditions caused by external environmental changes or stresses on humans, with genetic differences playing a role. Despite the fact that each rare ailment is uncommon, the overall burden of these diseases affects one out of every ten people.

An agnostic testing such as glycome, metabolome, exome, and inflamome analysis on individuals enrolled in the PUD to detect previously unknown and exceedingly rare genetic illnesses, as well as to find and understand disease pathways. The glycome is the set of all glycan sugar compounds that are either bound to proteins or lipids in cells or present as free oligosaccharides in body fluids, and it represents cellular processes of glycosylation and deglycosylation. Protein glycosylation is a posttranslationalmodification of proteins that can be divided into two types: N-linked glycosylation and O-linked glycosylation.

There has been a lot of work done on these pathways. Linking sugar chains to the nitrogen or hydroxyl groups of certain amino acids is known as N and O-linked glycosylation, respectively. N-linked glycan synthesis begins in the Endoplasmic Reticulum (ER) and continues in the Golgi apparatus, whereas O-linked glycan synthesis begins in either the ER or the Golgi apparatus. The formation of Glycophosphatidylinositol (GPI)-anchors, glycosphingolipids, and glycosaminoglycans, as well as O-GlcNAcylation, are other glycosylation routes. N and O-linked glycans are removed during protein turnover in the lysosome and during protein synthesis in the cytoplasm as a quality control by enzymes such N-Glycanase 1(NGLY1). The ER, Golgi, lysosomes, and vesicular transport, as well as the enzymes involved in nucleotide sugar synthesis and glycan chain formations, and the proteins involved in nucleotide sugar transport, are required for the synthesis of complex glycan structures and the maintenance of glycosylated proteins. Primary congenital abnormalities of glycosylation or deglycosylation (CDG), as well as detrimental effects on organelles involved in glycan metabolism, can be caused by genetic or environmental perturbations of these processes. This report details various underlying reasons of abnormal glycosylation that were discovered during a patient's agnostic screen.

Protein glycosylation (the addition of carbohydrates to proteins) is an important cellular process and one of the most common post-translational modifications in nature, with profound implications for organismal development, growth, and physiology. About 2% of all human genes code for glycosylationrelated proteins, while at least 50% of all cellular proteins are glycosylated, according to estimates. N-linked and O-linked glycosylation, as well as the Glycosyl Phosphatidyl Inositol (GPI) anchor manufacturing pathway, are all involved in Congenital Diseases of Glycosylation (CDGs). The increased use of nextgeneration sequencing technologies and Whole Exome Sequencing (WES) has resulted in a rise in the number of novel CDGs discovered, as well as an improvement in the diagnosis of previously undiagnosed CDGs. Furthermore, deregulation of glycosyltransferases has been linked to the development ofcomplex illnesses. Overall, the suggested that studying cellular glycosylation can help researchers better understand the etiology and pathophysiology of diseases that are now unidentified.